The health technology assessment agency has recommended in final draft guidance that the short-course oral therapy be used on the NHS as a first-line treatment option for adults with active relapsing‐remitting MS (RRMS) when high-efficacy disease-modifying therapies (DMTs) would be considered.
The drug, which was previously only recommended by NICE as an option for highly active RRMS, a more severe form of the neurological disorder, offers patients greater flexibility by reducing the frequency of hospital visits and daily treatment requirements…
